$355.20▲ 1.14 (0.32%)
Real-time prices · US MarketsHigh-quality business with 101% return on equity and 21% profit margins.
high leverage at 6.2× debt-to-equity.
Quality
9.3
Health
4.5
Growth
6.3
Valuation
6.8
Sentiment
5.6
Analyst Target
$352.50
▼ 0.8% from current
Price Chart
Latest News
Fundamentals
Trailing P/E
24.7×
price-to-earnings
Forward P/E
15.1×
next 12 months est.
Market Cap
$191.7B
market capitalization
Div Yield
2.84%
dividend yield
Profit Margin
21.0%
net profit margin
Gross Margin
71.4%
revenue minus COGS
ROE
101.3%
return on equity
Beta
0.42
vs S&P 500
52-Week Range
$268 — $391
annual min — max
EPS — Estimate vs Actual
Frequently Asked Questions
What do analysts say about Amgen Inc. right now?
Amgen Inc.'s Q·Score is 6.7/10 (Neutral), reflecting its current fundamentals, analyst data, and valuation metrics. High-quality business with 101% return on equity and 21% profit margins. Key area to monitor: high leverage at 6.2× debt-to-equity. This is an informational data summary only and does not constitute financial advice. Always do your own research before making any investment decision.
What is the analyst price target for AMGN?
The consensus price target for AMGN is $352.50, based on ratings from 30 Wall Street analysts. This is 0.8% below the current price of $355.20. Price targets are forward-looking estimates and not guarantees of future performance.
Is AMGN overvalued or undervalued?
Amgen Inc. (AMGN) scores in line with sector averages on valuation metrics. Its forward P/E ratio stands at 15.1×.
When does Amgen Inc. report its next earnings?
Amgen Inc.'s next earnings report is expected on approximately August 4, 2026.
What is Amgen Inc.'s profit margin?
Amgen Inc. has a net profit margin of 21.0%, which is considered high and reflects strong pricing power. Its gross margin stands at 71.4%, indicating a high-margin business model.
What is AMGN's dividend yield?
Amgen Inc. currently offers a dividend yield of 2.84%, which is above the typical market average dividend yield. Dividend yields can change based on price movements and company payout decisions.
Is Amgen Inc.'s revenue growing?
Amgen Inc. is reporting modest revenue growth of 5.8%. Earnings are also growing at 4.4%, indicating improving profitability.
How much debt does Amgen Inc. have?
Amgen Inc. has a debt-to-equity ratio of 6.24×, reflecting a high debt-to-equity ratio, which increases financial risk especially in rising rate environments. Its current ratio is 1.26×, suggesting it should be monitored for near-term liquidity.
Compare AMGN with any stock